Literature DB >> 31345791

Clinical meaning of PROMIS pain domains for children with sickle cell disease.

Ashima Singh1, Julie A Panepinto1,2.   

Abstract

The Patient Reported Outcomes Measurement Information System (PROMIS) pain interference and pain behavior domains are valid and reliable for children with sickle cell disease (SCD). However, clinical interpretation of the scores is unknown. The objective of this study was to determine the clinical meaning of PROMIS pain scores for children with SCD. We used 2 approaches to determine clinical meaning: dichotomization of item responses and T-score ranges. T-score ranges determined thresholds for no/mild, moderate, and severe pain. We compared the proportion of patients who needed pain medications among pain severity groups using χ2/Fisher's exact tests. The study included 117 children (mean age, 11.5 years [standard deviation, 2.9 years]). Using the dichotomization approach, 43 children had pain interference T-scores ≤48 reflecting minimal pain, and 30 children had T-scores >60 reflecting substantial pain. For pain behavior, 34 children had T-scores ≤41 reflecting minimal problems, and 23 patients had T-scores >57 reflecting substantial problems with pain. Using T-score ranges, clinical thresholds of no/mild and severe pain interference were determined as ≤48.3 and >63.6, respectively. The thresholds for no/mild and severe pain behavior were ≤41.3 and >57.3, respectively. Overall, the proportion of patients who took pain medications was significantly different among those with no/mild, moderate, and severe pain as identified by pain interference (P = .002) and pain behavior domains (P = .0113). We identified T-scores for PROMIS pain domains that facilitate clinical interpretation and provide necessary information for PROMIS users in a clinical setting.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31345791      PMCID: PMC6693018          DOI: 10.1182/bloodadvances.2019000381

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  19 in total

1.  Making quality-of-life results more meaningful for clinicians.

Authors:  Madeleine T King; Peter M Fayers
Journal:  Lancet       Date:  2008-03-01       Impact factor: 79.321

2.  PROMIS Pediatric Pain Interference Scale: an item response theory analysis of the pediatric pain item bank.

Authors:  James W Varni; Brian D Stucky; David Thissen; Esi Morgan Dewitt; Debra E Irwin; Jin-Shei Lai; Karin Yeatts; Darren A Dewalt
Journal:  J Pain       Date:  2010-06-02       Impact factor: 5.820

3.  Health-related quality of life in children with sickle cell disease: child and parent perception.

Authors:  Julie A Panepinto; Kerry M O'Mahar; Michael R DeBaun; Fausto R Loberiza; J P Scott
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

4.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

5.  Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  Nan E Rothrock; Ron D Hays; Karen Spritzer; Susan E Yount; William Riley; David Cella
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

Review 6.  Health-related quality of life in sickle cell disease: past, present, and future.

Authors:  Julie A Panepinto; Melanie Bonner
Journal:  Pediatr Blood Cancer       Date:  2012-04-22       Impact factor: 3.167

7.  PedsQL™ sickle cell disease module: feasibility, reliability, and validity.

Authors:  Julie A Panepinto; Sylvia Torres; Cristiane B Bendo; Timothy L McCavit; Bogdan Dinu; Sandra Sherman-Bien; Christy Bemrich-Stolz; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2013-02-25       Impact factor: 3.167

8.  PedsQL™ Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity.

Authors:  Julie A Panepinto; Sylvia Torres; Cristiane B Bendo; Timothy L McCavit; Bogdan Dinu; Sandra Sherman-Bien; Christy Bemrich-Stolz; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2013-09-13       Impact factor: 3.167

9.  The performance of the PedsQL generic core scales in children with sickle cell disease.

Authors:  Julie A Panepinto; Nicholas M Pajewski; Lisa M Foerster; Raymond G Hoffmann
Journal:  J Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.289

10.  Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective.

Authors:  Holger J Schünemann; Elie A Akl; Gordon H Guyatt
Journal:  Health Qual Life Outcomes       Date:  2006-09-14       Impact factor: 3.186

View more
  2 in total

Review 1.  What is the future of patient-reported outcomes in sickle-cell disease?

Authors:  Sharon A Singh; Nitya Bakshi; Prashant Mahajan; Claudia R Morris
Journal:  Expert Rev Hematol       Date:  2020-10-15       Impact factor: 2.929

2.  Health-related quality of life in hemoglobinopathies: A systematic review from a global perspective.

Authors:  Francesca Rodigari; Giorgia Brugnera; Raffaella Colombatti
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.